News & Announcements

Weil Secures Jury Verdict of Willful Infringement, with Lost Profits and Royalties, for Cancer Diagnostics Company ArcherDX

On August 27, 2021, Weil won an important $5M jury verdict for ArcherDX and Harvard’s Massachusetts General Hospital in a competitor patent infringement dispute with German conglomerate Qiagen. The willful infringement verdict found every question in our client’s favor and awarded even more damages than our client requested. The dispute involves DNA/RNA tests that are helping to revolutionize cancer diagnostics and treatment, which were invented by two prominent Harvard Medical School professors on the staff at Mass General.

The value of the verdict is very significant given that the cancer testing market is in its infancy, and even more so with a 7% royalty rate. Key to our success at trial was harnessing compelling testimony from both the inventors and business entrepreneurs who invested considerable time, knowledge and money into building a successful start-up and life-saving technology.

The trial team was led by Ed Reines, Co-Head of Weil’s Patent Litigation and Life Sciences practices.

Legalese